Member Info for OAPK20

MURFU ticker

Up 76% to $17.44-$19.39

Let’s see if it holds in aftermarket

Joe😂😂😂

China licence deal alone worth potentially £300M pa but you will settle for 7p a share.

TF your not the CEO😁

8th September 2023 - Presentation.

"We are Entering New Categories Through M&A

Identify fast growing and/or game changing technologies that can scale

Integrate acquisitions that fill product or technology gaps Strengthen diagnostic and analytical capabilities that

leverage our consumables portfolio

Support continued expansion of footprint in Europe and Asia Extract maximum value from recent acquisitions"

The Western blot is widely used in the study of protein biochemistry, but it is notoriously labor-intensive, and it is limited in its reproducibility and quantification, among many other challenges. By contrast, capillary-based protein separation and immunodetection, known as Simple Western™, overcomes many of the challenges associated with the traditional Western blot, and it is quickly gaining traction as a replacement for traditional Western blot analysis. The advantages that capillary-based immunoassay offers include ease of use, automation, reproducibility, quantification, and even built-in total protein normalization. In this chapter, we describe protocols for the two basic types of capillary-based immunodetection assays, one by molecular weight separation and the other by charge separation. In both methods, protein samples are separated in the capillary followed seamlessly by immunodetection with chemiluminescent or fluorescent antibodies for highly sensitive and specific detection of target proteins.

Vince. At some point the market will get excited. Reckon if CIZ can attain the 95% accuracy on a “the Gold standard for protein detection” or even above 80-98% in a clinical trial then it’s a game changer. Even then though it’s only IF the test sells.

(OT - NCYT 2p - £12 with COVID tests during the pandemic. Difference with CIZ product is the demand for annual screening for Lung Cancer worldwide is not going away)

https://www.nature.com/articles/nmeth.f.353

Western blotting is considered the gold standard for protein detection and characterization. Although improvements to individual aspects of Western methodologies have been developed in recent years, none has integrated the entire process onto a single platform. ProteinSimple™ has developed Simple Western™ assays for protein sizing and quantitative immunodetection as an alternative to traditional Western blot analysis. Assays are performed on Simon™, an instrument that integrates and automates all manual operations associated with Western blotting.

Simple Western Assays

Our Simple Western systems automate the entire Western blot workflow and allow you to obtain faster results in 3 hours with only 3µL of sample. Multiplex across three different detection channels with precision and industry-leading fluorescence detection sensitivity. Double your data with RePlex™ and analyze your samples by both immunoassay and total protein in the same run.

£10

Re CIZ Put option. Any thoughts?

Is it just same price or same price and terms ?

“ (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock (each, a “Warrant”), for a purchase price of $10.00 per Unit (the “Purchase Price”) in the Private Placement.“

CIZ RNS 19/12/22 - Should Cizzle exercise the Option, Conduit will acquire both the Economic Interest and Royalty Sharing Agreement from Cizzle for a total consideration of approximately GBP3.25 million, to be satisfied through the issuance of new shares in Conduit (the "Consideration Shares") at the same price per Conduit share that a proposed US$27 million private investment round in Conduit, led by new and existing investors of Conduit (the "PIPE Investment"), is to be effected at, as further described below.

MURF SEC Filing 13/9/23 - In connection with the transactions contemplated by the Merger Agreement, on September 13, 2023, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with Nirland Limited, a Guernsey company (the “Private Placement Investor”), which is in lieu of, and on substantially similar terms as, the previously entered into private placement for $27 million. Pursuant to the Subscription Agreement, the Private Placement Investor has agreed to purchase $20 million (the “Private Placement”) units of the Company (the “Units”), with each Unit consisting of (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock (each, a “Warrant”), for a purchase price of $10.00 per Unit (the “Purchase Price”) in the Private Placement.

Dv just basic calcs.

It depends on the new listing commencing Stage 3 trial and gaining FDA approval and whether CIZ hold until trial results or FDA approval.

Unlikely as they will need to monetise the shares to progress their CIZ1b test

Antelope - CIZ have a put option to sell their interest in AZD1656 to Conduit Pharma when they list.

It’s £3.25M worth of shares at $10 per share.

Roughly $4,058,242.50 / $10 - for 405,824 shares in Conduit on listing. If CIZ execute the Put. Valued at higher lower depending on price the sp achieves on the NASDAQ.

At $20 - $8,116,480

At $5 - $2,029,120

Proforma Impact on Reduced Private Placement Amount

If the revision to the Private Placement amount from $27 million to $20 million had been reflected in the Prospectus dated August 11, 2023, the impact on the Assuming No Redemption Scenario and the Assuming Maximum Redemption Scenario in the unaudited pro forma condensed combined financial information would have been as follows:

● cash and cash equivalents would have been reduced by $7.0 million (in both redemption scenarios),

● additional paid-in-capital would have been reduced by $6.9 million (in both redemption scenarios),

● the derivative warrant liability would have been reduced by $0.1 million (in both redemption scenarios),

● the number of shares of New Conduit common stock assumed issued and outstanding would have been reduced from:

○ 75.2 million to 74.5 million in the Assuming No Redemption Scenario, and

○ 73.1 million to 72.4 million in the Assuming Maximum Redemption Scenario.

As a result of the revised Private Placement amount, New Conduit will continue to initiate its clinical trial programs following the Business Combination and may look to raise additional capital at such time as required to fund certain trials where necessary.

Https://news.spacconference.com/2023/09/13/murphy-canyon-adds-20m-to-pipe-supporting-conduit-deal/

The Warrant will be exercisable for a period of five years after the completion of the Business Combination and will have an exercise price of $11.50 per share, subject to adjustment as set forth in the Warrant for stock splits, stock dividends, recapitalizations and similar customary adjustments. The Private Placement Investor may exercise each Warrant on a cashless basis if the shares of common stock underlying the Warrants are not then registered pursuant to an effective registration statement. The Private Placement Investor has contractually agreed to restrict its ability to exercise the Warrants such that the number of shares of the common stock held by the Private Placement Investor and its affiliates after such exercise does not exceed the beneficial ownership limitation set forth in the Warrant which may not exceed 4.99% of then issued and outstanding shares of the Company’s common stock.

On September 13, 2023, St George Street Capital (“St George Street”), an existing holder of Conduit’s ordinary shares, sold 78 of the ordinary shares of Conduit held by it to the Private Placement Investor in a transaction unrelated to the Private Placement. As a result, St George Street is anticipated to hold approximately 4,749,313 shares of New Conduit common stock following the Business Combination, which is anticipated to be approximately 7.3% of the issued and outstanding shares of common stock of New Conduit.

Item 1.01. Entry into a Material Definitive Agreement.

As previously reported by Murphy Canyon Acquisition Corp., a Delaware corporation (the “Company”), on Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2022, November 14, 2022, January 30, 2023 and May 11, 2023, the Company entered into an Agreement and Plan of Merger, dated as of November 8, 2022, as amended on January 27, 2023 and May 11, 2023 (as amended, the “Merger Agreement”), with Conduit Merger Sub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of the Company (the “Merger Sub”), and Conduit Pharmaceuticals Limited, a Cayman Islands exempted company (“Conduit”), pursuant to which, among other matters, subject to the terms and conditions therein, the Company intends to consummate its initial business combination with Conduit (the “Business Combination”). The Company following the Business Combination is referred to herein as “New Conduit.”

In connection with the transactions contemplated by the Merger Agreement, on September 13, 2023, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with Nirland Limited, a Guernsey company (the “Private Placement Investor”), which is in lieu of, and on substantially similar terms as, the previously entered into private placement for $27 million. Pursuant to the Subscription Agreement, the Private Placement Investor has agreed to purchase $20 million (the “Private Placement”) units of the Company (the “Units”), with each Unit consisting of (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock (each, a “Warrant”), for a purchase price of $10.00 per Unit (the “Purchase Price”) in the Private Placement. The Subscription Agreement contains registration rights, pursuant to which within fifteen (15) business days after the closing of the Private Placement, the Company will use reasonable best efforts to file with the SEC a registration statement registering the resale of shares of common stock included in the Units and the shares of common stock issued and issuable upon exercise of the Warrants. The closing of the Private Placement is conditioned on there not being a suspension of the qualification of common stock for offering or sale or trading in any jurisdiction, or the initiation or threatening of any material legal proceeding, no legal prohibitions to consummate the Business Combination, and all conditions precedent to the closing of the Business Combination set forth in the Merger Agreement having been satisfied or waived.

The Warrant will be exercisable for a period of five years after the completion of the Business Combination and will have an exercise price of $11.50 per share, subject to adjustment as set forth in the Warrant for stock splits, stock dividends, recapitalizations and similar customary adjustment

Presidio Property Trust Don’t say that Joe but as sponsors of MURF they do say

“ A full description of the terms of the proposed business combination, which is expected to close in the second half of 2023 subject to the satisfaction of multiple conditions, ”

Https://feeds.issuerdirect.com/news-release.html?newsid=8575770127765518

“ A full description of the terms of the proposed business combination, which is expected to close in the second half of 2023 subject to the satisfaction of multiple conditions, ”

About Presidio Property Trust

Presidio is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio’s model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. Our office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California. While geographical clustering of real estate enables us to reduce our operating costs through economies of scale by servicing several properties with less staff, it makes us susceptible to changing market conditions in these discrete geographic areas, including those that have developed as a result of COVID-19. Presidio is also the sponsor of the Special Purpose Acquisition Company (SPAC) Murphy Canyon Acquisition Corp. (NASDAQ: MURF), which currently holds approximately $23.3 million in trust. Murphy Canyon Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The SPAC has entered into a definitive business combination agreement with Conduit Pharmaceuticals Limited (Conduit). A full description of the terms of the proposed business combination, which is expected to close in the second half of 2023 subject to the satisfaction of multiple conditions, including approval of the business combination by the SPAC’s shareholders, is provided in the registration statement on Form S-4 that the SPAC has filed with the SEC. For more information on Presidio, please visit the Company’s website at https://www.PresidioPT.com.

Widglide - given your claim to a high average sp are you buying to average down ?